{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:50:39Z","timestamp":1792158639157,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Complex karyotype (CK) is a strong predictor of early progression and poor survival in chronic lymphocytic leukaemia (CLL), including during targeted therapy. Minimal residual disease (MRD)\u2013guided therapy may improve outcomes by enabling deeper remissions and limiting clonal evolution. We present the final results of a prospective MRD\u2010guided ibrutinib and venetoclax (IVen) compared with a retrospective cohort treated with ibrutinib monotherapy (Imono). Eligible patients had CLL with high CK (\u22655 aberrations) or CK with deletion 17p. The IVen cohort received 3\u2009months of ibrutinib followed by up to 24\u2009months of IVen combination therapy or until three consecutive undetectable MRD (uMRD) bone marrow assessments. Patients with detectable MRD after 24\u2009months continue ibrutinib alone. Baseline characteristics showed numerical differences between cohorts that did not reach statistical significance. A total of 106 patients were included (IVen\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200950; Imono\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200956). With a median follow\u2010up of 42.1\u2009months, IVen significantly improved progression\u2010free survival (PFS) (33.9\u2009months vs. NR; hazard ratio [HR] 0.23,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and overall survival (OS) (47\u2009months vs. NR; HR 0.48,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0186) compared with Imono, although comparisons are limited by the retrospective control design. uMRD was achieved in 66% of patients with IVen. These results support MRD\u2010adapted IVen as an optimal strategy for high\u2010risk CLL.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70761","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:54:47Z","timestamp":1787183687000},"page":"1664-1672","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal residual disease\n                    <scp>\u2013<\/scp>\n                    guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype"],"prefix":"10.1111","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8794-0120","authenticated-orcid":false,"given":"Maria","family":"Kislova","sequence":"first","affiliation":[{"name":"Botkin Hospital  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-4510","authenticated-orcid":false,"given":"Elena","family":"Dmitrieva","sequence":"additional","affiliation":[{"name":"Botkin Hospital  Moscow Russia"},{"name":"Russian Medical Academy of Continuous Professional Education  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-5746","authenticated-orcid":false,"given":"Elena","family":"Naumova","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Pochtar","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Lugovskaya","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Kobzev","sequence":"additional","affiliation":[{"name":"Botkin Hospital  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Loban","sequence":"additional","affiliation":[{"name":"Botkin Hospital  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3337-2487","authenticated-orcid":false,"given":"Maria","family":"Gladysheva","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Obukhova","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-3334","authenticated-orcid":false,"given":"Bella","family":"Biderman","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-9187","authenticated-orcid":false,"given":"Andrey","family":"Sudarikov","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-1636","authenticated-orcid":false,"given":"Egor","family":"Volchkov","sequence":"additional","affiliation":[{"name":"Botkin Hospital  Moscow Russia"},{"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology  Moscow Russia"},{"name":"Laboratory of Single Cell Biology, Research Institute of Molecular and Cellular Medicine Patrice Lumumba Peoples' Friendship University of Russia  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-3583","authenticated-orcid":false,"given":"Maria","family":"Ivanova","sequence":"additional","affiliation":[{"name":"R.M. Gorbacheva Research Institute Pavlov University  Saint\u2010Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-6050","authenticated-orcid":false,"given":"Vadim","family":"Ptushkin","sequence":"additional","affiliation":[{"name":"Botkin Hospital  Moscow Russia"},{"name":"Russian Medical Academy of Continuous Professional Education  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Medicine University of Padova  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2490-1263","authenticated-orcid":false,"given":"Eugene","family":"Nikitin","sequence":"additional","affiliation":[{"name":"Botkin Hospital  Moscow Russia"},{"name":"Russian Medical Academy of Continuous Professional Education  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010536"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015014"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019634"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-873083"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032160"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00429-z"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010236"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7036"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504341"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","unstructured":"SiddiqiT TamCS AllanJN KippsTJ OpatS TedeschiA et\u00a0al.First\u2010line ibrutinib (IBR) + venetoclax (VEN) for patients (pts) with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): efficacy and safety results from CAPTIVATE MRD cohort. 25th Congress of the European Hematology Association Virtual Edition. HemaSphere.2020;4:1\u20131168.https:\/\/doi.org\/10.1097\/HS9.0000000000000404","DOI":"10.1097\/HS9.0000000000000404"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1649"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","unstructured":"KislovaM DmitrievaE NaumovaE PochtarM LugovskayaS KobzevY et\u00a0al.Updated results of combination treatment with ibrutinib and venetoclax in patients with chronic lymphocytic leukemia and complex karyotype. EHA2024 Congress. European Hematology Association. EHA2024 Hybrid Congress. HemaSphere.2024;8:e104.https:\/\/doi.org\/10.1002\/hem3.104","DOI":"10.1002\/hem3.104"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01241-1"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.313"},{"key":"e_1_2_11_22_1","unstructured":"ObukhovaT NikitinE KislitsynaM DmitrievaE KislovaM NovikovaT et\u00a0al.Complex karyotype is a strong predictor of short\u2010term progression in chronic lymphocytic leukemia patients treated with ibrutinib. EHA; 06\/12\/20202020."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015180"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207452"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194593"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01802-y"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196931"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0444-6"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379966"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-546150"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.357"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005943"},{"key":"e_1_2_11_34_1","unstructured":"VisentinA ChatzikonstantinouT ScarfoL TalimtziP AngelopoulouM ArpasT et\u00a0al.Treatability with ibrutinib plus venetoclax in patients with CLL in the real\u2010world. The ERIC international ThRIVe study. ASH2025."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70761","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70761","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:09:20Z","timestamp":1792156160000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/bjh.70761"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70761","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"2026-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}